Insider Transactions in Q1 2022 at Regenxbio Inc. (RGNX)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 20
2022
|
Vittal Vasista Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,900
+15.55%
|
$0
$0.85 P/Share
|
|
Jan 03
2022
|
Vittal Vasista Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,900
+6.29%
|
-
|
|
Jan 03
2022
|
Kenneth T. Mills |
BUY
Grant, award, or other acquisition
|
Direct |
35,796
+10.36%
|
-
|
|
Jan 03
2022
|
Patrick J. Christmas Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,900
+25.62%
|
-
|
|
Jan 03
2022
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,700
+26.9%
|
-
|
|
Jan 03
2022
|
Steve Pakola Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,900
+34.17%
|
-
|
|
Jan 03
2022
|
Steve Pakola Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,598
-16.23%
|
$52,734
$33.75 P/Share
|
|
Jan 03
2022
|
Curran Simpson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,700
+28.29%
|
-
|
|
Jan 01
2022
|
Kenneth T. Mills |
SELL
Payment of exercise price or tax liability
|
Direct |
3,636
-1.31%
|
$116,352
$32.7 P/Share
|
|
Jan 01
2022
|
Patrick J. Christmas Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,332
-8.14%
|
$42,624
$32.7 P/Share
|
|
Jan 01
2022
|
Olivier Danos Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,221
-6.23%
|
$39,072
$32.7 P/Share
|
|
Jan 01
2022
|
Steve Pakola Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,152
-10.47%
|
$36,864
$32.7 P/Share
|
|
Jan 01
2022
|
Curran Simpson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,332
-7.51%
|
$42,624
$32.7 P/Share
|